AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29545772 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (0.5 ml bolus injection)
Number of subjects: 10
Study 29545951 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injections in HFS patients
Number of subjects: 24
Study 29545951 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers without Botox injections
Number of subjects: 24
Study 29545953 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT) with real-time feedback-controlled dosimetry
Number of subjects: 16
Study 29546247 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly in-person and telephone-based guidance on calorie-restricted diets and aerobic exercise
Number of subjects: 40
Study 29546247 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 29546316 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 2
Study 29546671 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 228
Study 29546671 — intervention group
Group type: COMPARATOR
Intervention: Radiologic examination using water-soluble contrast (1st group)
Number of subjects: 228
Study 29546671 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy (2nd group)
Number of subjects: 228
Study 29547638 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional reused ventilator system
Number of subjects: 0
Study 29547638 — intervention group
Group type: COMPARATOR
Intervention: Disposable closed ventilator-suction system
Number of subjects: 0
Study 29548277 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variants in hERG (rs36210421 and rs1805123)
Number of subjects: 7224
Study 29548287 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced ready-to-use supplementary food (RUSF)
Number of subjects: 540
Study 29548287 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-Soy Blend Plus Plus (CSB++)
Number of subjects: 540
Study 29548287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles micronutrient powders
Number of subjects: 540
Study 29548287 — intervention group
Group type: COMPARATOR
Intervention: Unimproved diet
Number of subjects: 540
Study 29548300 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH 1-34 + WBV-exercise
Number of subjects: 40
Study 29548300 — intervention group
Group type: COMPARATOR
Intervention: PTH 1-34
Number of subjects: 40
Study 29548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke extract (CSE) exposure in bronchial epithelial cells
Number of subjects: 0
Study 29548305 — intervention group
Group type: EXPERIMENTAL
Intervention: CC16 immunostaining intensity in bronchial epithelium
Number of subjects: 0
Study 29548561 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiation therapy (3-DCRT)
Number of subjects: 35
Study 29548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 3394
Study 29548752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D concentration
Number of subjects: 1191
Study 29548900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery (phacoemulsification and intraocular lens implantation)
Number of subjects: 26
Study 29548900 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 29548934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide once daily
Number of subjects: 62
Study 29548934 — intervention group
Group type: COMPARATOR
Intervention: 4 mg glimepiride together with 1 g metformin twice daily
Number of subjects: 62
Study 29549159 — intervention group
Group type: EXPERIMENTAL
Intervention: Utomilumab (PF-05082566)
Number of subjects: 0
Study 29549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 254
Study 29549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 254
Study 29549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusions
Number of subjects: 254
Study 29549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion until splenectomy
Number of subjects: 254
Study 29549175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 3 mg/kg
Number of subjects: 16
Study 29549175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 16
Study 29549175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg, expansion cohort)
Number of subjects: 16
Study 29549175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (all doses)
Number of subjects: 16
Study 29549598 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel, applied once daily for the first 4 weeks and twice daily for the following 20 weeks.
Number of subjects: 0
Study 29549598 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 0
Study 29549862 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus erlotinib (gem/erlotinib)
Number of subjects: 150
Study 29549862 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX (for patients switched from gem/erlotinib)
Number of subjects: 150
Study 29550052 — intervention group
Group type: EXPERIMENTAL
Intervention: Topological Data Analysis (TDA)
Number of subjects: 202
Study 29550177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stents for endovascular reconstruction of the IVC
Number of subjects: 62
Study 29550195 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine in 2-10-year-olds
Number of subjects: 1537
Study 29550195 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine in 9-23-month-olds
Number of subjects: 1537
Study 29550259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education program for children (PNE4Kids)
Number of subjects: 18
Study 29550316 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions
Number of subjects: 72
Study 29550316 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive hemodynamic assessment
Number of subjects: 72
Study 29550316 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of noninvasive hemodynamic assessments
Number of subjects: 72
Study 29550319 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial shear wave imaging (SWI)
Number of subjects: 80
Study 29550382 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity
Number of subjects: 167
Study 29550382 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg orally twice daily
Number of subjects: 167
Study 29550630 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor conditioning regimen
Number of subjects: 18
Study 29550642 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty (n=27)
Number of subjects: 47
Study 29550642 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis (n=20)
Number of subjects: 47
Study 29550773 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postoperative delirium (POD)
Number of subjects: 200
Study 29550773 — intervention group
Group type: COMPARATOR
Intervention: Patients without postoperative delirium (POD)
Number of subjects: 200
Study 29550773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition measured by Trails A and B and Stroop Color and Word Test
Number of subjects: 200
Study 29550773 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by Veteran's RAND 12-item Health Survey
Number of subjects: 200
Study 29550773 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident dementia measured by Short Blessed Test
Number of subjects: 200
Study 29551225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flubio® (Influenza HA Trivalent) vaccine, administered in 1 or 2 doses with a 28-day interval.
Number of subjects: 405
Study 29551225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flubio® (Influenza HA Trivalent) vaccine
Number of subjects: 405
Study 29551311 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index z-score (BMIZ)
Number of subjects: 447
Study 29551311 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 447
Study 29551311 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in BMIZ
Number of subjects: 447
Study 29551338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg per day, adjusted to maintain a therapeutic range of 6-15 ng/mL) for 12 months
Number of subjects: 40
Study 29551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores for food enjoyment and lower scores for satiety responsiveness, slowness in eating, and food fussiness at Time 2
Number of subjects: 195
Study 29551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher slowness in eating scores
Number of subjects: 195
Study 29551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster eating rates
Number of subjects: 195
Study 29551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI children with greater food enjoyment and food responsiveness scores
Number of subjects: 195
Study 29551401 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-s time delay on the delivery of regular snacks
Number of subjects: 32019
Study 29551401 — intervention group
Group type: EXPERIMENTAL
Intervention: $0.25 discount on healthy snacks
Number of subjects: 32019
Study 29551401 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 25-s time delay and $0.25 discount
Number of subjects: 32019
Study 29551401 — intervention group
Group type: EXPERIMENTAL
Intervention: $0.25 tax on regular snacks
Number of subjects: 32019
Study 29551401 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 25-s time delay and $0.25 tax
Number of subjects: 32019
Study 29551401 — intervention group
Group type: COMPARATOR
Intervention: Overall vending sales and revenue
Number of subjects: 32019
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary marine omega-3 PUFA in CHNS
Number of subjects: 50149
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) in CHNS
Number of subjects: 50149
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) in NHANES
Number of subjects: 50149
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) in NHANES
Number of subjects: 50149
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid in NHANES and CHNS
Number of subjects: 50149
Study 29551407 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA at an omega-6/omega-3 ratio of 6-10 in CHNS
Number of subjects: 50149
Study 29551711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine users
Number of subjects: 257
Study 29551711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole ketamine users
Number of subjects: 257
Study 29551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib 40-340 mg orally twice daily (Arm II)
Number of subjects: 58
Study 29551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib 10-180 mg orally once daily (Arm I)
Number of subjects: 58
Study 29551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib 8-32 mg intravenously once daily (Arm III)
Number of subjects: 58
Study 29551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib (all arms)
Number of subjects: 58
Study 29551893 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma SFRP5 level
Number of subjects: 1745
Study 29551893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma SFRP5
Number of subjects: 1745
Study 29552014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional (IL) treatment with ipilimumab
Number of subjects: 0
Study 29552014 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (ICIs)
Number of subjects: 0
Study 29552321 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily plus fotemustine 100 mg/m2 intravenously every three weeks
Number of subjects: 31
Study 29552321 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily plus fotemustine
Number of subjects: 31
Study 29552356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PRF) 10 mg BID
Number of subjects: 0
Study 29552356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29552422 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Empowerment Council (DEC) intervention, 12-week holistic, multimodality facilitated group intervention
Number of subjects: 51
Study 29552422 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 51
Study 29552422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DEC and control)
Number of subjects: 51
Study 29552569 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 followed by reintroduction of a platinum doublet after a brief priming period
Number of subjects: 1
Study 29552569 — intervention group
Group type: COMPARATOR
Intervention: Platinum doublet regimen
Number of subjects: 1
Study 29552996 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 208
Study 29553382 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1
Number of subjects: 525
Study 29553382 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2
Number of subjects: 525
Study 29553382 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA3
Number of subjects: 525
Study 29553382 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA6
Number of subjects: 525
Study 29553484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical brain-computer interfaces (BCIs)
Number of subjects: 2
Study 29553484 — intervention group
Group type: EXPERIMENTAL
Intervention: Features of extracellular waveforms
Number of subjects: 2
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of carotid intima-media thickness (c-IMT)
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV)
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip-line
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 1284
Study 29553852 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral PWV
Number of subjects: 1284
Study 29554265 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel low-profile, 22-Fr transapical delivery system with ACURATE neo™ transcatheter heart valve
Number of subjects: 60
Study 29554265 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural success in absence of major adverse cardiac and cerebrovascular events at 30 days
Number of subjects: 60
Study 29555305 — intervention group
Group type: COMPARATOR
Intervention: Any family history (FH)
Number of subjects: 6200
Study 29555305 — intervention group
Group type: COMPARATOR
Intervention: Premature family history (FH)
Number of subjects: 6200
Study 29555305 — intervention group
Group type: COMPARATOR
Intervention: Strong familial risk assessment (FRA)
Number of subjects: 6200
Study 29555305 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 6200
Study 29555620 — intervention group
Group type: EXPERIMENTAL
Intervention: mPCST intervention (Web-based mobile pain coping skills training)
Number of subjects: 36
Study 29555620 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 36
Study 29555835 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 362
Study 29555835 — intervention group
Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 362
Study 29555836 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-AVC thresholds for diagnosing severe AS (women 1377 Agatston unit, men 2062 Agatston unit)
Number of subjects: 918
Study 29555836 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-AVC thresholds
Number of subjects: 918
Study 29555989 — intervention group
Group type: EXPERIMENTAL
Intervention: pEBV DNA clearance ≤ 10 days and > 50% drop in sum of SUVmax of target lesions
Number of subjects: 58
Study 29555989 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PET-CT response and pEBV DNA clearance
Number of subjects: 58
Study 29556158 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% caloric restriction
Number of subjects: 12
Study 29556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training (EGT)
Number of subjects: 9
Study 29556414 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 9
Study 29556416 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Number of subjects: 409
Study 29556416 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W)
Number of subjects: 409
Study 29556416 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409
Study 29556416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 29556419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 49
Study 29556419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29556418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks plus csDMARDs
Number of subjects: 0
Study 29556418 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus csDMARDs
Number of subjects: 0
Study 29556695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 39
Study 29557387 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage adjustment during deep brain stimulation
Number of subjects: 6
Study 29557815 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label escitalopram for 14 weeks
Number of subjects: 83
Study 29557815 — intervention group
Group type: COMPARATOR
Intervention: Healthy control and psychiatric outpatient samples
Number of subjects: 83
Study 29558160 — intervention group
Group type: EXPERIMENTAL
Intervention: New Ultrasound Method for Estimating Dynamic Intrinsic Positive Airway Pressure
Number of subjects: 0
Study 29558274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist-led BRCAm testing pathway
Number of subjects: 700
Study 29558281 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with concurrent radiotherapy (RT) to the chest wall and regional lymph nodes (50 Gy plus a 10-Gy boost)
Number of subjects: 30
Study 29558533 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular borders
Number of subjects: 49
Study 29558533 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular borders
Number of subjects: 49
Study 29558533 — intervention group
Group type: EXPERIMENTAL
Intervention: Splitting borders
Number of subjects: 49
Study 29558533 — intervention group
Group type: COMPARATOR
Intervention: Comparison between border types
Number of subjects: 49
Study 29558650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 145
Study 29558650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 145
Study 29558650 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 145
Study 29558650 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional clarity changes
Number of subjects: 145
Study 29558650 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to emotions
Number of subjects: 145
Study 29558966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) at 35 Gy in 5 fractions
Number of subjects: 12
Study 29558982 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-risk-reduction intervention combined with financial literacy intervention, vocational training program, and matched savings (HIVRR+MF)
Number of subjects: 350
Study 29558982 — intervention group
Group type: COMPARATOR
Intervention: HIV-risk-reduction intervention alone (HIVRR)
Number of subjects: 350
Study 29559372 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic catatonia (PC)
Number of subjects: 56
Study 29559372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataphasia (C)
Number of subjects: 56
Study 29559372 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia (both PC and C)
Number of subjects: 56
Study 29559423 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg)
Number of subjects: 30
Study 29559423 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg)
Number of subjects: 30
Study 29559423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29559561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 29559773 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modeling approaches to define distinct disease groups in patients with obstructive lung disease using medical history and spirometric data.
Number of subjects: 0
Study 29559773 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modeling approaches (asthma model, COPD model)
Number of subjects: 0
Study 29559773 — intervention group
Group type: EXPERIMENTAL
Intervention: PLS-DA
Number of subjects: 0
Study 29560093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 43
Study 29560379 — intervention group
Group type: COMPARATOR
Intervention: Baseline normalized brain volume (high)
Number of subjects: 0
Study 29560379 — intervention group
Group type: COMPARATOR
Intervention: Brain volume loss
Number of subjects: 0
Study 29560379 — intervention group
Group type: COMPARATOR
Intervention: Baseline T2 lesion volume
Number of subjects: 0
Study 29560743 — intervention group
Group type: EXPERIMENTAL
Intervention: Liletta (levonorgestrel 52 mg IUS)
Number of subjects: 0
Study 29561066 — intervention group
Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.12 mg/kg body weight ×2
Number of subjects: 8